NCT04607954View on ClinicalTrials.gov

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

May 19, 2027

Study Completion Date

April 19, 2031

Conditions

Platinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Extensive Stage Lung Small Cell CarcinomaRefractory Extensive Stage Lung Small Cell Carcinoma

Interventions

BIOLOGICAL

Durvalumab

Given IV

DRUG

Lurbinectedin

Given IV

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester